

CELL THERAPEUTICS INC  
Form DEFA14A  
June 04, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**SCHEDULE 14A**

(RULE 14a-101)

**INFORMATION REQUIRED**

**IN PROXY STATEMENT**

**SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934**

Filed by the Registrant:

Filed by a Party other than the Registrant:

Check the appropriate box:

Preliminary Proxy Statement

**Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

**Cell Therapeutics, Inc.**

Edgar Filing: CELL THERAPEUTICS INC - Form DEFA14A

(Name of registrant as specified in its charter)

(Name of person(s) filing proxy statement, if other than the registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

ON JUNE 4, 2010, CELL THERAPEUTICS, INC. (THE COMPANY ) ISSUED THE FOLLOWING PRESS RELEASE REGARDING THE COMPANY S SPECIAL MEETING OF SHAREHOLDERS.

**Cell Therapeutics, Inc.**

Making cancer more treatable

501 Elliott Ave. W. #400 T 206.282.7100  
Seattle, WA 98119 F 206.272.4010

**Cell Therapeutics Adjourns Special Meeting of Shareholders Until June 29, 2010**

SEATTLE, WA, June 4, 2010 Cell Therapeutics, Inc. (Nasdaq and MTA:CTIC) (the Company ) today announced that the Company has adjourned today s Special Meeting of Shareholders (the Special Meeting ) to 10:00 am Pacific Daylight Time, Tuesday, June 29, 2010. The Company s proxy materials previously filed with the Securities and Exchange Commission (the SEC ) on February 23, 2010 and the proposals being submitted to a vote of the shareholders at the Special Meeting as described in such proxy materials remain unchanged. The Company encourages those shareholders that held shares as of February 19, 2010, the record date of the Special Meeting, to vote their shares on the proposals.

*This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading prices of the Company s securities. The risks and uncertainties include the risk that the Company might not be able to continue to raise additional capital as needed to fund its operations, and other risk factors listed or described from time to time in the Company s filings with the SEC, including, without limitation, its most recent filings on Forms 10-K, 10-Q and 8-K. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.*

\* \* \*

**Media Contact:**

Dan Eramian

T: 206.272.4343

C: 206.854.1200

F: 206.272.4434

E: [deramian@ctiseattle.com](mailto:deramian@ctiseattle.com)

[www.celltherapeutics.com/press\\_room](http://www.celltherapeutics.com/press_room)

**Investors Contact:**

Ed Bell

T: 206.272.4345

Lindsey Jesch Logan

T: 206.272.4347

F: 206.272.4434

E: [invest@ctiseattle.com](mailto:invest@ctiseattle.com)

[www.celltherapeutics.com/investors](http://www.celltherapeutics.com/investors)